Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group JF Forbes, J Cuzick, etal: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month ...

The researchers found that adding AZD8931 did not work better than anastrozole alone. The trial recruited 359 women. Their average age was 61. They all had breast cancer that was hormone receptor ...

These complications were considered unlikely to influence the antitumour effects of anastrozole, and no significant difference between treatment groups was observed in the other demographic ...

06) at the 47-month follow-up visit. The overall reduction in incidence of contralateral invasive breast cancer with anastrozole treatment was significant at 33 and 47 months of follow-up (HR 0.30 ...

The trial evaluated switching to the camizestrant combination versus continuing standard-of-care treatment with an aromatase inhibitor (AI) (anastrozole or letrozole) in combination with a CDK4/6 ...

At a median follow-up of 44.2 months, results showed that the 4-year iDFS rates in premenopausal patients were 90.6% with the Kisqali-plus-NSAI regimen with letrozole or anastrozole (1115 patients) ...

NHS England welcomed the decision, saying that anastrozole could be an option for around 289,000 women and, if a quarter of them take the drug, it could help prevent around 2,000 cases of breast ...

Novartis Canada is pleased to announce that Health Canada has granted a Notice of Compliance (NOC) for KISQALI® (ribociclib ...

A month after the Eastern Cape Department of Health promised that they had paid the overdue bills that delayed the delivery of chemotherapy drugs to Nelson Mandela Bay hospitals and that the issue ...

Daily doses of 150-300 mg once daily have been shown to reduce the size and number of colorectal adenomas. 54 Prolonged treatment can maintain this effect: One small series reported no advanced ...